⁶⁸Ga-grazytracer PET for noninvasive assessment of response to immunotherapy in solid tumors and lymphomas: a phase 1/2 clinical trial.

ABSTRACT: To tackle the clinical challenge of noninvasively assessing immunotherapy efficacy in patients, here we used positron emission tomography (PET) with ⁶⁸Ga-grazytracer, which targets granzyme B, a crucial effector molecule secreted by activated CD8⁺ T cells. In this phase 1/2 clinical trial (NCT05000372) involving a diverse cohort of 24 patients with solid tumors and lymphomas who received immunotherapies, including immune checkpoint inhibitors (either alone or with chemotherapies) and chimeric antigen receptor-T cell therapy, we examined the in vivo behaviors of ⁶⁸Ga-grazytracer. Primary endpoints were safety, biodistribution, granzyme B specificity, and the predictive utility of ⁶⁸Ga-grazytracer, while secondary endpoint was the relationship betw

SUBMITTER: Shen X 

PROVIDER: S-EPMC11467221 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature